Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618001889246
Ethics application status
Approved
Date submitted
12/11/2018
Date registered
20/11/2018
Date last updated
14/01/2024
Date data sharing statement initially provided
20/11/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
New parameters for brain stimulation in the treatment of depression
Scientific title
Translation of preclinical findings: the effect of low intensity repetitive Transcranial Magnetic Stimulation (rTMS) on depression score and biomarkers in patients with major depression.
Secondary ID [1] 296522 0
none
Universal Trial Number (UTN)
U1111-1223-2586
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Depression 310304 0
Condition category
Condition code
Mental Health 309034 309034 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
rTMS will be delivered in a head to head trial at an intensity of 50mT (estimated at 50mT at the level of the cortical surface) as an add on to the standard FDA-approved protocol of 100-120% of Motor Threshold equivalent to ~1000mT; (Gaynes et al., 2014; O’Reardon et al., 2007; Price et al., 2010) in a patient cohort, to compare outcomes to the standard protocol alone.

Treatment resistant patients (n=40; male and female) will be recruited through collaboration with Dr Greg Price and Clinical Psychiatrist, Dr Mark McAndrew at the SCGH; Mental Health Unit; Neurophysiology Service. Dr Greg Price will deliver the treatment protocol and Dr Mark McAndrew will do psychological assessments.

The study will consist of 4-6 weeks of treatment comprising 20-30 sessions (weekdays only) of rTMS to the left dorsolateral prefrontal cortex. Patients will be randomly assigned to the standard protocol (100-120%MT;1000mT) or add-on protocol (standard protocol+50mT) stimulation group.

Standard protocol: patients will receive 75 trains of rTMS at 10Hz equivalent to ~ 1000mT:100-120% MT, with an inter-train interval of 30 seconds comprising of a total of 20-30 sessions (weekdays for 4-6 weeks)

Add on protocol: patients will receive alternating trains during the session of standard protocol rTMS: (1 train of rTMS at 10Hz at 100-120%MT) followed by 50 mT rTMS (1 train of rTMS at 10Hz at ~10% Maximum Stimulator Output*) with an inter-train interval of 15 seconds repeated till a total of 150 trains of 10Hz stimulation is provided comprising of a total of 20-30 sessions (weekdays for 4-6 weeks)

*10% Maximum Stimulator output is equivalent to ~50 mT at cortex.
Intervention code [1] 312833 0
Treatment: Devices
Comparator / control treatment
Active control / Standard protocol: patients will receive 75 trains of 100-120%MT;1000mT rTMS at 10Hz, with an inter-train interval of 30 seconds
Control group
Active

Outcomes
Primary outcome [1] 307997 0

Outcome Name: Depression
Metric/method of measurement: The primary endpoint will be the percentage change in HAM-D-21 response (score), defined by a significant change from the initial score on the Hamilton Depression Scale (HAM-D-21)
Timepoint [1] 307997 0
Timepoint: Directly following end of 4 week treatment period
Primary outcome [2] 308140 0
number of remissions defined by a HAM-D-21 score of <8 directly following 4 week treatment period and 6 months after;
Timepoint [2] 308140 0
Time points: Baseline, Immediately after end of 4 week rTMS treatment period and 6 months after treatment commencement.
Secondary outcome [1] 353611 0
the change and presence of predictive markers of the therapeutic response: serum biomarkers (a amino-nbutyric acid)
Timepoint [1] 353611 0
Time points: Baseline, Immediately after end of 4 week rTMS treatment period and 6 months after treatment commencement.
Secondary outcome [2] 354103 0
the change and presence of predictive markers of the therapeutic response: serum biomarkers (3-methylhistidine)
Timepoint [2] 354103 0
Time points: Baseline, Immediately after end of 4 week rTMS treatment period and 6 months after treatment commencement.

Eligibility
Key inclusion criteria
ICD-10-AM diagnosis of major depression. Subsequent depression scale scores will act as a validation check (any discrepancies to be reviewed by PI), but initial inclusion will be purely by clinical diagnosis. Aged above 18 years

Participants need not meet formal criteria for treatment resistance, but must have shown an unsatisfactory response to a previous treatment regime. The judgement to recommend a participant for this trial is, therefore, explicitly a clinical decision by the recruiting physician. However, we do require that the antidepressant medication regime be stable in type and dosage for 4 weeks prior to the rTMS trial.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Presence of cardiac pacemakers, medication pumps, cochlear implants or metal objects in the head or eyes that could be dangerous if heated or moved by the magnetic pulses.
Significant medical illness, substantial risk of suicide, current psychosis, current substance dependence, a history of seizures, epilepsy, stroke or major head trauma, or a history of alcohol dependence.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Random sequence prior to recruitment.
central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
SPSS will be used to randomly generate a 1:1
list of treatment numbers (10Hz=0;
Variable=1). As participants sign the consent
form, they are allocated a sequence number
that corresponds to a treatment number.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
The person doing assessment will be blind to treatment. The assessor is not in the treatment area so does not hear the treatment
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Power analysis based on our published LI-rTMS data in preclinical models indicates that 16 individuals/group for behaviour (equivalent of behavioural changes in humans), or 8 individuals per group for biochemical/neurological changes (equivalent for blood samples in humans), will provide 0.8 power to detect changes of 20%.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
9/02/2021
Actual
9/02/2021
Date of last participant enrolment
Anticipated
1/06/2023
Actual
7/08/2023
Date of last data collection
Anticipated
15/03/2024
Actual
Sample size
Target
40
Accrual to date
Final
42
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 12364 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 24624 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 301107 0
Charities/Societies/Foundations
Name [1] 301107 0
Perron Institute for Translational Neuroscience
Country [1] 301107 0
Australia
Primary sponsor type
University
Name
University Of Western Australia
Address
The University of Western Australia,
35 Stirling Highway,
Crawley WA, 6009
Country
Australia
Secondary sponsor category [1] 300718 0
None
Name [1] 300718 0
Address [1] 300718 0
Country [1] 300718 0
Other collaborator category [1] 282316 0
Government body
Name [1] 282316 0
North metropolitan health service, mental health
Address [1] 282316 0
UU Block, SCGH Mental Health Unit Verdun Street NEDLANDS WA 6009
Country [1] 282316 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 301857 0
North Metropolitan Area Mental Health Services Human Research Ethics Committee [EC00273]
Ethics committee address [1] 301857 0
Ethics committee country [1] 301857 0
Australia
Date submitted for ethics approval [1] 301857 0
20/11/2018
Approval date [1] 301857 0
20/12/2018
Ethics approval number [1] 301857 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 88338 0
A/Prof Jennifer Rodger
Address 88338 0
School of Biological Sciences M317
The University of Western Australia, 35 Stirling Highway, Crawley WA 6009
Country 88338 0
Australia
Phone 88338 0
+61 8 6488 2245
Fax 88338 0
Email 88338 0
jennifer.rodger@uwa.edu.au
Contact person for public queries
Name 88339 0
Jennifer Rodger
Address 88339 0
School of Biological Sciences M317
The University of Western Australia, 35 Stirling Highway, Crawley WA 6009
Country 88339 0
Australia
Phone 88339 0
+61 8 6488 2245
Fax 88339 0
Email 88339 0
jennifer.rodger@uwa.edu.au
Contact person for scientific queries
Name 88340 0
Jennifer Rodger
Address 88340 0
School of Biological Sciences M317
The University of Western Australia, 35 Stirling Highway, Crawley WA 6009
Country 88340 0
Australia
Phone 88340 0
+61 8 6488 2245
Fax 88340 0
Email 88340 0
jennifer.rodger@uwa.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
baseline and final depression rating
When will data be available (start and end dates)?
from the end date of project up to 5 years following
Available to whom?
Researchers in the Field
Available for what types of analyses?
Meta analyses, Subscale analyses.
How or where can data be obtained?
Electronic by request


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
5943Study protocolNo citation kerry.leggett@uwa.edu.au NA 376320-(Uploaded-27-11-2019-13-08-12)-Study-related document.docx
5944Informed consent form  kerry.leggett@uwa.edu.au 376320-(Uploaded-27-11-2019-13-11-01)-Study-related document.docx
5945Ethical approval  kerry.leggett@uwa.edu.au



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.